Advertisement

Medical Oncology

, 36:41 | Cite as

First experience of durable cytoreduction in chronic lymphoid leukemia with 177Lu-DOTATATE

  • Tijana Savovic
  • John O. Prior
  • Marie Nicod-Lalonde
  • Alberic Bressoud
  • Stéphane Roux
  • Niklaus SchaeferEmail author
  • Marie Meyer
Short Communication
  • 44 Downloads

Abstract

This is the first described case of effective and durable cytoreduction after PRRT with 177Lu-DOTATATE in a 75-year-old female, with B cell chronic lymphoid leukemia, and well-differentiated metastatic neuroendocrine tumor.

Keywords

PET/CT 117Lu-DOTATATE Chronic lymphoid leukemia Neuroendocrine tumor PRRT 

Notes

Compliance with ethical standards

Conflict of interest

All the authors declared that they have no conflict of interest.

References

  1. 1.
    Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125–35.CrossRefGoogle Scholar
  2. 2.
    Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:2416–23.CrossRefGoogle Scholar
  3. 3.
    Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of 177Lu-DOTATATE for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376:125–35.CrossRefGoogle Scholar
  4. 4.
    Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42:5–19.CrossRefGoogle Scholar
  5. 5.
    Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:2124–30.CrossRefGoogle Scholar
  6. 6.
    Sabet A, Ezziddin K, Pape U-F, Ahmadzadehfar H, Mayer K, Pöppel T, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med Off Publ Soc Nucl Med. 2013;54:1857–61.Google Scholar
  7. 7.
    Ferone D, Lombardi G. Colao A [Somatostatin receptors in immune system cells]. Minerva Endocrinol. 2001;26:165–73.PubMedGoogle Scholar
  8. 8.
    Hiruma K, Koike T, Nakamura H, Sumida T, Maeda T, Tomioka H, et al. Somatostatin receptors on human lymphocytes and leukaemia cells. Immunology. 1990;71:480–5.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Witzig TE, Letendre L, Gerstner J, Schroeder G, Mailliard JA, Colon-Otero G, et al. Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders: results of a phase II North Central Cancer Treatment Group trial. J Clin Oncol. 1995;13(8):2012–5.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Tijana Savovic
    • 1
  • John O. Prior
    • 1
  • Marie Nicod-Lalonde
    • 1
  • Alberic Bressoud
    • 2
  • Stéphane Roux
    • 3
  • Niklaus Schaefer
    • 1
    Email author
  • Marie Meyer
    • 1
  1. 1.Nuclear Medicine Department and Molecular ImagingCHUVLausanneSwitzerland
  2. 2.Medical Oncology, Clinique Bois-CerfLausanneSwitzerland
  3. 3.Interal Medicine, Centre Médical du BouveretBouveretSwitzerland

Personalised recommendations